Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay

Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity

(2016) Anette Karle et al.   mAbs

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics

(2016) Marisa K. Joubert et al.   PLoS One

Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective

(2015) Yow-Ming C. Wang et al.   AAPS Journal

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

(2015) B. Rup et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity

(2015) Karin A van Schie et al.   mAbs

Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells

(2014) Matthias Wölfl et al.   Nature Protocols

Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors

(2013) A. C. Moss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up

(2013) Eva L Kneepkens et al.   ANNALS OF THE RHEUMATIC DISEASES

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

(2013) Vibha Jawa et al.   CLINICAL IMMUNOLOGY

Comment on "The Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response Magnitude"

(2013) B. Maillere   JOURNAL OF IMMUNOLOGY

Infliximab Inhibits Activation and Effector Functions of Peripheral Blood T Cellsin vitrofrom Patients with Clinically Active Ulcerative Colitis

(2013) R. Dahlén et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

The Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response Magnitude

(2012) M. K. Jenkins et al.   JOURNAL OF IMMUNOLOGY

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

(2012) M Lundkvist et al.   Multiple Sclerosis Journal

Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis

(2012) Clara de Andrés et al.   PLoS One

Dissecting the T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT

(2012) Donald D. Anthony et al.   Cells

Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors

(2011) Stephanie Delluc et al.   FASEB JOURNAL

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis

(2011) Carolina Holmén et al.   Multiple Sclerosis Journal

Overcoming immunogenicity associated with the use of biopharmaceuticals

(2011) Michael G Tovey et al.   Expert Review of Clinical Pharmacology

Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential

(2010) S. Delluc et al.   BLOOD

Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics

(2010) Danika Wullner et al.   CLINICAL IMMUNOLOGY

Impact of Product-Related Factors on Immunogenicity of Biotherapeutics

(2010) Satish Kumar Singh   JOURNAL OF PHARMACEUTICAL SCIENCES

The immunogenicity of humanized and fully human antibodies

(2010) Fiona A. Harding et al.   mAbs

T cell epitope: Friend or Foe? Immunogenicity of biologics in context☆

(2009) Constanze A. Weber et al.   ADVANCED DRUG DELIVERY REVIEWS

Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis

(2009) H. M. Baldwin et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis

(2009) R M Thurlings et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity of rituximab in patients with severe pemphigus

(2009) Enno Schmidt et al.   CLINICAL IMMUNOLOGY

B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses

(2009) Kathleen P. Pratt et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Human naive and memory CD4+T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells

(2009) Rebekka Geiger et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Optimization of a dendritic cell-based assay for the in vitro priming of naïve human CD4+ T cells

(2009) Janice M. Moser et al.   JOURNAL OF IMMUNOLOGICAL METHODS

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

(2008) C P Denton et al.   ANNALS OF THE RHEUMATIC DISEASES

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

(2008) T R D J Radstake et al.   ANNALS OF THE RHEUMATIC DISEASES